H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.
The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts
CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck
The U.S. Supreme Court is reviewing a contentious bankruptcy settlement involving Purdue Pharma, the maker of OxyContin, and its owners, the Sackler family.
Valneva SE (NASDAQ: VALN) reported antibody persistence data 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, further supporting the anticipated long-term durability of the immune response and in line with positive twelve-month persistence data the company reported
Alterity Therapeutics Inc (NASDAQ: ATHE) shares are trading higher after the company announced that ATHE434 new data in a Parkinson's disease primate model were presented at the Future of Parkinson's
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) announced topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with